3 Undervalued Pharmaceuticals Stocks for Monday, November 09
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, November 09 based on AAII’s Stock Grades.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Commentary & Analysis
Why Arvinas, Inc.’s (ARVN) Stock Is Down 7.38%
As of Tuesday, November 03, Arvinas, Inc.’s ARVN share price has dipped by 7.38%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About Arvinas, Inc.'s Q4 Earnings
Arvinas, Inc.'s fiscal Q4 earnings report was released on Tuesday, November 03. Let's dive in to see if (ARVN) missed or beat analyst's expectations.Rosalio Madrigal
Why Arvinas, Inc.’s (ARVN) Stock Is Down 5.47%
As of Monday, November 02, Arvinas, Inc.’s ARVN share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Michael Rose
Why Arvinas, Inc.’s (ARVN) Stock Is Down 5.05%
As of Friday, October 23, Arvinas, Inc.’s ARVN share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $446.6 | $447.9 | 37% |
|
| Shares Out (Mil) | 65.4 | 46.7 | 53% |
|
| Institutional Ownership | 96.9% | 80.9% | 71% |
|
| Float (Mil) | 56.9 | 46.8 | 49% |
|
| Beta | 1.80 | 0.74 | 88% |
|
| Avg Daily Volume (000s) | 1,093 | 342 | 69% |
|
| Price Change (52-week) |
(34.5%) | 54.7% | 27% |
|
| Growth | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 58.9% | 6.1% | 97% |
|
| Net Income (5yr) | 7.5% | (1.6%) | 51% |
|
| EPS (5yr) | 17.7% | 15.0% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.2%) | (15.1%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 12 | |
| Current EPS | ($0.767) | $0.159 | ($3.177) | |
| Month Ago EPS | ($0.927) | ($0.137) | ($3.232) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.852) | ($0.065) | ($3.117) | |
| Year/Year Chg | (6.9%) | (113.9%) | 140.1% | |
| Financials | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $275 | $303 | 35% |
|
| Net Income (TTM) (Mil) | ($10) | ($10) | 29% |
|
| EPS (TTM) | ($0.147) | ($0.600) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($158) | ($7) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($13) | $1 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $6 | 25% |
|
| Enterprise Value (Q1) (Mil) | ($65) | $408 | 1% |
|
| Valuation | ARVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.87 | 2.19 | 22% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 96.7% | 69.5% | 96% |
|
| Net Margin | (3.5%) | 3.9% | 26% |
|
| ROA | (1.3%) | (22.7%) | 35% |
|
| ROE | (1.8%) | (25.0%) | 33% |
|
| Liabilities to Assets | 15.4% | 31.8% | 10% |
|
| F-Score | 5 | 3 | 50% |
|
Arvinas, Inc. did not pass any screens on 11/13/2026.
